IYH iShares U.S. Healthcare ETF
Company Analysis
Latest News
Eli Lilly’s Mounjaro wins FDA heart approval, boosting blockbuster market lead
The FDA approved an expanded indication for Eli Lilly’s Mounjaro to reduce the risk of major adverse cardiovascular events (MACE). This approval applies to...
🟢 Health ETF (IYH) is trading 5.9% up in pre-market after FDA approval for Mounjaro’s cardiovascular-risk reduction
IYH is trading at $76.90 (+5.88%) in pre-market after Eli Lilly received FDA approval for Mounjaro to reduce cardiovascular-event risk. - The approval...
Revolution Medicines wins FDA approval, doubling survival in pancreatic cancer patients
The U.S. Food and Drug Administration granted expedited approval to Revolution Medicines' new drug, daraxonrasib (brand name: Rasonque). This first-of-its-kind...
Quest Diagnostics to Offer First FDA-Cleared Alzheimer's Blood Test, Replacing Invasive Scans
Quest Diagnostics will begin offering Roche's Elecsys Phospho-Tau (217P) Plasma (pTau217) assay. This is the first and only FDA-cleared blood test designed to...
🔴 Health ETF (IYH) is trading 3% down in pre-market on August 24, 2026 amid risk aversion
IYH is trading at $71.67, down 3.00% from the August 21 close amid global risk aversion. - U.S. futures and technology lower; elevated long-term Treasury...
J&J Secures EU Approval for TECVAYLI as Second-Line Myeloma Therapy
Johnson & Johnson received European Commission approval for an expanded indication of its cancer drug TECVAYLI (teclistamab). The approval authorizes the...
🟢 Health ETF (IYH) is trading 3.32% up in pre-market on Trump’s nomination of Dr. Heidi Overton
IYH is trading at $75.40 (+3.32%), driven by President Trump’s nomination of Dr. Heidi Overton to lead the FDA. - The nomination could end the agency’s...
Trump Nominates Dr. Heidi Overton for FDA, Signaling Vaccine Policy Shift
President Donald Trump nominated Dr. Heidi Overton to lead the Food and Drug Administration. Dr. Overton currently serves as a White House health policy aide...
Moderna, Merck shares surge on successful Phase 3 cancer vaccine trial
Merck and Moderna announced that their individualized neoantigen therapy, intismeran, met its primary endpoint in a Phase 3 melanoma trial. The combination of...
🟢 Health ETF (IYH) is trading 3.29% up today on melanoma-vaccine optimism
IYH is trading 3.29% up today as healthcare benefits from investor rotation away from technology amid elevated Treasury yields, geopolitical uncertainty, and...
BioMarin buys Alesta for $275M, targeting first oral rare bone drug
BioMarin Pharmaceutical signed a definitive agreement to acquire clinical-stage biotech Alesta Therapeutics. The deal centers on ALE1, an oral small molecule...
Bristol-Myers Squibb Wins FDA Approval for Iberdomide, Using Landmark Cancer Endpoint
The FDA approved Bristol-Myers Squibb’s iberdomide combination therapy for adults with relapsed or refractory multiple myeloma. This regimen combines...
UMCG backs low-cost digoxin, cutting heart failure hospitalizations by 25%
UMCG cardiologists found low-dose digoxin reduces heart failure hospitalizations by approximately 25%. Nature Medicine and the Journal of the American Medical...
Replimune Gains FDA Approval for TUDRIQEV, Transitioning to Commercial Stage
The FDA granted Replimune Group Inc. accelerated approval for its oncolytic immunotherapy, TUDRIQEV. The drug treats patients with advanced cutaneous melanoma...
Lantheus Wins FDA Approval for Tauklarify to Detect Alzheimer’s Protein
The U.S. Food and Drug Administration (FDA) approved Tauklarify (florquinitau F 18) for use in positron emission tomography (PET) scans. Lantheus Holdings...
Definium Therapeutics Hits Phase III Goal for LSD-Derived Anxiety Drug
Definium Therapeutics announced its LSD-derived oral drug, DT120, met the primary endpoint in the Phase III VOYAGE trial for Generalized Anxiety Disorder...
Eli Lilly sues six firms for selling unapproved obesity drug, retatrutide
Eli Lilly filed six lawsuits against U.S. medical spas and online sellers for marketing unapproved versions of retatrutide. The legal action targets a growing...
Cardinal Health jumps, driven by profit beat and $5 billion buyback
Cardinal Health (NYSE: CAH) reported fourth-quarter fiscal 2026 adjusted earnings of $2.91 per share. This result surpassed the Wall Street consensus estimate...
Bristol Myers Squibb invests $2.3B in Texas to accelerate drug production
Bristol Myers Squibb (BMS) will invest $2.3 billion to build a new manufacturing campus in Houston, Texas. The multi-modal facility will produce both small...
AstraZeneca eyes Bristol Myers merger, creating $400B oncology powerhouse
AstraZeneca is discussing a merger with U.S. rival Bristol Myers Squibb. The potential deal would value the combined pharmaceutical giant at nearly $400...